MHRA approves Moderna’s COVID-19 vaccine in the UK

Published: 8-Jan-2021
Regulatory

The UK is the fifth jurisdiction to authorise Moderna’s vaccine, following the United States, Canada, Israel and the European Union

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Moderna’s mRNA vaccine against COVID-19 for use under Regulation 174. The temporary authorisation permits the supply of the vaccine in Great Britain and is based upon the advice of the UK Commission on Human Medicines.

“We appreciate the confidence shown by the UK MHRA in COVID-19 Vaccine Moderna with this decision, which marks an important step forward in the global fight against COVID-19,” said Stéphane Bancel, CEO of Moderna. “I want to thank the MHRA and the Commission on Human Medicines’ reviewers for their tireless efforts. The authorisation of a product developed by Moderna is a significant milestone on the company’s 10-year journey, and I would like to thank all our colleagues that have helped us get to this point.”

The United Kingdom government has also exercised its option to purchase an additional 10 million doses of the vaccine, bringing its confirmed order commitment to 17 million doses. The first deliveries of the vaccine to the UK from Moderna’s non-US supply chain are expected to commence early in 2021.

  • Companies:
  • Moderna Therapeutics
See more

You may also like

Regulatory

Moderna's updated COVID-19 vaccine gets the green light from the FDA

Read more
This year's version of the KP.2-targeting vaccine will endeavour to curb local COVID-19 outbreaks

Trending Articles

  1. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  3. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
  4. Accelerating and enhancing toxicology assessments Infographic guides users through ToxHQ’s speedy assessment features
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

Moderna's updated COVID-19 vaccine gets the green light from the FDA

This year's version of the KP.2-targeting vaccine will endeavour to curb local COVID-19 outbreaks
Distribution

Moderna receives positive opinion from the EMA for Spikevax

Moderna has revealed the European Medicine's Agency (EMA) has provided positive opinion on its COVID-19 vaccine Spikevax's marketing authorisation
Regulatory

Moderna senior executive to speak at the ISPE conference

As Chief Technical Operations and Quality Officer, Andres is responsible for the supply of products required for the company’s preclinical and clinical development programmes
Regulatory

European Commission purchases additional Moderna vaccine doses

Under the terms of the agreement, the European Commission has the option to purchase an additional 150 million doses to be delivered in 2022
Regulatory

European Commission authorises Moderna COVID vaccine

The EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for vaccine based on the totality of scientific evidence shared by the company
Regulatory

Pharma CEOs pledge to uphold scientific standards for COVID vaccine

The pledge outlines "a united commitment to uphold the integrity of the scientific process"
Regulatory

Accelerating and enhancing toxicology assessments

Infographic guides users through ToxHQ’s speedy assessment features
Subscribe now